EUCTR2007-001794-28-NL进行中（未招募）不适用
Endothelial Function following stenting with Genous vs Drug-Eluting Stents - Vasomotion
OrbusNeich Medical BV0 个研究点目标入组 36 人开始时间: 2007年11月8日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Currently receiving statin therapy for at least 2 weeks prior to the index procedure;
- •2.18 to 85 years of age;
- •3.Symptomatic ischemic heart disease (CCS class 1–4, Braunwald class IB, IC, and/or objective evidence of myocardial ischemia);
- •4.Single de novo lesions; Patients with an additional lesion in another vessel can be included, however, the vasomotion study is to be performed on only one lesion which is identified by the investigator, prior to randomization, as the one which is most suitable for vasomotion study.
- •5.Target lesion is located in a native coronary artery, which can be covered by one single;
- •6.Reference vessel diameter ? 2.5 and ? 4.0 mm by visual estimate;
- •7.Acceptable candidate for coronary artery bypass surgery (CABG);
- •8.Target lesion stenosis is >50% and <100% (minimum TIMI flow I at the time of the PCI
- •procedure) (visual estimate);
- •9.The patient is willing to comply with the specified follow-up evaluation;
- •10.The patient has been informed of the nature of the study agrees to its provisions and has provided written informed consent, approved by the appropriate Ethics Committee (EC).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Women who are pregnant or women of childbearing potential who do not use adequate contraception;
- •2.A Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure, unless the CK and CK-MB enzymes or Troponin levels are less than twice the Upper Normal Limit;
- •3.Uncontrolled hypertension or currently treated with three or more hypertensive medications. Patients unable to discontinue beta blockers, calcium antagonists, nitrates, ACE inhibitors or angiotensin II inhibitors for 48 hours prior to the scheduled 6 month angiographic follow-up should not be included.
- •4.Impaired renal function (creatinine > 3.0 mg/dl or 265 µmol/l);
- •5.Any patient who has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 or a WBC of < 3,000 cells/mm3;
- •6.Documented or suspected liver disease (including laboratory evidence of hepatitis);
- •7.Recipient of heart transplant;
- •8.Any patient who previously received murine therapeutic antibodies and exhibited sensitization through the production of Human Anti-mouse Antibodies (HAMA);
- •9.Patient with a life expectancy less than the follow-up period (6 months);
- •10.Known allergies to aspirin, clopidogrel bisulphate (Plavix?) and ticlopidine (Ticlid?), heparin, or stainless steel;
- •11.Known side-effects (clinically demonstrated by biological tests, elevated CK and liver assessments) to statins and previous attempts to treat side-effects were unsuccessful;
- •12.Any significant medical condition which in the Investigator’s opinion may interfere with the patient’s optimal participation in the study;
- •13.Currently participating in an investigational drug or another device study that has not completed the primary endpoint, or subject to inclusion in another investigational drug or another device study during follow-up of this study;
- •14.Patients currently undergoing chemotherapy or immunosuppressant therapy;
- •15.Patients with known malignancy(ies).
- •Angiographic exclusion criteria:
- •16.Unprotected left main coronary artery disease with ? 50% stenosis;
- •17.Ostial target lesion;
- •18.Totally occluded target vessel (TIMI flow 0);
- •19.Target lesion has excessive tortuousity unsuitable for stent delivery and deployment;
- •20.Target lesion involves bifurcation class D & type G including a side branch ? 2.5mm in diameter (either stenosis of both main vessel and major side branch or stenosis of just major side branch) that would require stenting of diseased side branch;
- •21.Angiographic evidence of thrombus in the target vessel;
- •22.A significant (> 50%) stenosis proximal or distal to the target lesion;
- •23.Impaired runoff in the treatment vessel with diffuse distal disease;
- •24.Left Ventricular ejection fraction ? 30%;
- •Other exclusion criteria:
- •25.Pre-treatment with devices other than balloon angioplasty, although direct stenting is allowed;
- •26.Prior stent within 5mm of target lesion;
- •Intervention of another lesion within 6 months prior to or after the index procedure.
研究者
相似试验
招募中
3 期
Comparative outcomes of endovascular stenting of venous anastomosis versus open repair after surgical thrombectomy of thrombosed arteriovenous hemodialysis graft, a randomized control trial.Early thrombosis of hemodialysis bypass graft in patients with ESRDbypass graftthrombosisstentingTCTR20240524003Faculty of medicine Ramathibodi hospital Mahidol university44
已完成
不适用
The utility of endothelial function assessed by EndoPAT2000 in estimating the risk of venous thromboembolism after lower extremity arthroplastyosteoarthritisJPRN-UMIN000009787Yokohama City University Medical Center200
进行中（未招募）
不适用
Assessment of endothelial function in patients with psoriasis before and after Etanercept treatment - NDmoderate to severe psoriasisMedDRA version: 6.1Level: PTClassification code 10037153EUCTR2006-007011-24-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI40
已完成
不适用
Impact of Stent Diameter on Vascular Response After Self-expanding Paclitaxel-eluting Stent Implantation in the Superficial Femoral Artery: An Optical Frequency Domain Imaging StudyPeripheral Artery DiseaseJPRN-UMIN000015485Hyogo College of Medicine20
招募中
不适用
ate Vascular Response Following Endovascular Treatment with Drug-coating Balloon for Femoropopliteal Artery Lesions as Assessed by Intravascular UltrasoundPeripheral Artery DiseaseJPRN-UMIN000046511Department of Cardiovascular Medicine, Shinshu University Hospital100